Navigation Links
VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
Date:2/6/2008

Disease Altering Treatment Shows Ability to Prevent HIV from Replicating

GAITHERSBURG, Md., Feb. 6 /PRNewswire/ -- VIRxSYS Corporation, a privately held company developing gene therapies for HIV and genetic diseases, presented results from its Phase II trial of VRX496, a gene therapy for the treatment of AIDS, at the 2008 Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, MA.

"This appears to be a significant demonstration of slowing and possibly halting the replication of the infectious HIV virus in humans," said Dr. Gary Blick, Medical Director, Circle Medical LLC. "VRX496 appears to cause wt-HIV particles to lose their envelopes and the in vivo pressure delivered by a patient's own modified cells leads to massive quasispecie reductions and production of impaired and less replicative virions. This treatment shows tremendous promise."

VRX496 has the potential to change HIV/AIDS care. Currently there are a variety of drugs available for HIV-infected patients, but all have long-term complications. To date, there have been no reported adverse events in any patient receiving VRX496 in clinical trials. In addition, VRX496 does not require daily administration.

"We are proving the effectiveness of our lentiviral vector approach in attacking HIV," said Dr. Laurent Humeau, VP of R&D for VIRxSYS. "Our lentiviral vector VRX496 appears to sustain expression of the RNA antisense targeting the HIV envelope for a long period of time, with a measurable effect on the HIV replicative fitness up to 3 years following a single injection. We believe this will prove to be an important step in the treatment of this disease."

VRX496 is a different viral vector than those used in previous gene therapy trials. VRX496 is derived from HIV-1 itself and has it disease-causing elements removed. Currently, VRX496 is being investigated as a therapeutic treatment (a treatment for those already infected with HIV). Unlike other vir
'/>"/>

SOURCE VIRxSYS Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
3. Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research
4. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
5. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
6. Xenon Announces Appointment of VP, Discovery Research
7. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
8. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
9. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
10. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
11. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Francisco, California (PRWEB) July 28, 2014 ... USD 604.40 billion by 2020, according to a new ... coupled with the rising demand for effective vaccines and ... patients with unmet medical needs is expected to drive ... the need to enhance agricultural productivity via the use ...
(Date:7/26/2014)... Albany, NY (PRWEB) July 26, 2014 ... 2020 provides key market data on the Canada ... in millions of US dollars, volume (in units) ... segments - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy ... Browse Full Report at http://www.marketresearchreports.biz/analysis/213254 . , ...
(Date:7/25/2014)... , July 25, 2014 Research ... "Global Metabolomics Market 2014-2018" report to ... Metabolomics or Metabonomics is the ... has become a new experimental technique that is ... environmental sciences. Metabolites are small molecules that are ...
(Date:7/25/2014)... TEL AVIV, Israel , July 25, 2014 /PRNewswire/ ... a clinical-stage biopharmaceutical company focused on the development and ... of liver diseases and cholesterol gallstones, today announced financial ... First Half 2014 Financial Summary: , Reported ... 30, 2014, compared with $137,000 at December 31, 2013.  ...
Breaking Biology Technology:Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... Kristin Lucas, ClearTrial Senior Director of Clinical Services, will lead a ... Cash Flow and Accruals" at the CBI Forecasting & Budgeting conference. ... over clinical trial budgets and improve management of clinical trial cash ... ...
... of $0.44 -- increase of 110% from prior year , ... KNSY ), a leading medical technology company that provides ... today reported the results for its second quarter and first six ... , Record EPS of ...
... Calif., Jan. 28 NeuroFocus, the world leader in,the ... named,preeminent cognitive neuroscientist John Polich, Ph.D., as its Director ... company made this selection as it ramps up the ... the United Kingdom, France, Italy, Germany,Japan, Korea, India, and ...
Cached Biology Technology:ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference 2ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference 3Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 2Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 3Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 4Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 5Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 6Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 7Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 8Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 9Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 10Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 11Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 12Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 13Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 14Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 15Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 16Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 17Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 18NeuroFocus Names John Polich, World-Renowned Scientist in Brain Function and Cognition, to Head Global NeuroLab Operations 2NeuroFocus Names John Polich, World-Renowned Scientist in Brain Function and Cognition, to Head Global NeuroLab Operations 3
(Date:7/27/2014)... Dinosaurs might have survived the asteroid strike that wiped ... or later in history, scientists say. , A fresh ... has helped palaeontologists to build a new narrative of ... , They found that in the few million years ... Earth was experiencing environmental upheaval. This included extensive volcanic ...
(Date:7/27/2014)... CANCER RESEARCH UK scientists at Barts Cancer Institute have ... make cancer therapy significantly more effective, according to research ... at Barts Cancer Institute, part of Queen Mary University ... adhesion kinase (FAK), signals the body to repair itself ... damaging DNA. When the researchers removed FAK from blood ...
(Date:7/25/2014)... on this false-color image from the Terra satellite show the ... of wildfires in Eastern Russia. The burn scars show ... The wildfires have broken across the remote parts of ... false-color image from the MODIS instrument, it is still ... continue. Two recent image features noted below show the devastating ...
Breaking Biology News(10 mins):Dinosaurs fell victim to perfect storm of events, study shows 2New drug target can break down cancer's barrier against treatment 2
... chronic health condition that affects about one in four military ... of several factors, which differed in importance depending upon the ... Baylor University study. , Published online today in ... links between GWI and veterans, locations during the war. ...
... Call a bird "birdbrained" and they may call "fowl." Cornell ... birds is not linked to overall brain size, but to ... Songbirds with upper brain regions that are larger in ... songs. Higher brain areas control the majority of cognitive and ...
... SALT LAKE CITY, Sept. 19, 2011 University ... through walls now are aiming the technology at a ... adults with sleep apnea and babies at risk of ... uses off-the-shelf wireless transceivers similar to those used in ...
Cached Biology News:Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study 2Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study 3Size matters: Length of songbirds’ playlists linked to brain region proportions 2Catching a breath -- wirelessly 2Catching a breath -- wirelessly 3Catching a breath -- wirelessly 4Catching a breath -- wirelessly 5
... gun low-pressure system, 220-240 V, is used for ... handheld device employs an adjustable helium pulse to ... from the inner wall of a small plastic ... be used for in situ, in vitro, in ...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse monoclonal antibody raised against a partial recombinant NR4A2. NCBI Entrez Gene ID = NR4A2...
... also offers a DNA sequencing service. We ... plasmids, PCR products, BACs, etc. Our DNA ... as purified plasmids or purified PCR products. ... optimized for automated reaction setup and dye ...
Biology Products: